# Japan Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Japan HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Japan (JPN)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $14.4B
- Products: 49
- Buyer markets: 26
- Average CAGR: +29.9%
- Global sector size: $763.9B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $282.4B | $3.9B | $102.5B | +8.7% | 17 | +1.0% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $144.8B | $3.9B | $53.1B | +11.9% | 13 | +1.1% |
| HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $29.9B | $443.9K | $48.0B | -3.9% | 4 | +0.0% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $28.6B | $134.8M | $33.1B | +14.7% | 4 | +0.5% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $19.4B | $22.8M | $23.0B | +0.1% | 3 | +0.1% |
| HS 300220 - Vaccines: for human medicine | $25.9B | $8.3M | $21.6B | -1.5% | 5 | +0.0% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $15.4B | $11.1M | $15.5B | -3.0% | 2 | +0.1% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $26.4B | $59.7M | $14.9B | +6.5% | 5 | +0.2% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $24.4B | $232.9M | $14.4B | -1.4% | 7 | +0.6% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $6.8B | $5.4M | $9.6B | +1.9% | 2 | +0.1% |
| HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $6.3B | $583.2M | $9.4B | +84.6% | 4 | +9.3% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $10.1B | $493.0K | $8.9B | +50.0% | 4 | +0.0% |
| HS 282200 - Cobalt oxides and hydroxides: commercial cobalt oxides | $4.1B | $26.9K | $7.7B | -15.5% | 2 | +0.0% |
| HS 300339 - Medicaments: containing hormones (excluding insulin), (but not containing antibiotics), for therapeutic or prophylactic uses, not packaged for retail sale | $3.4B | $204.5 | $6.7B | -26.1% | 1 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $11.9B | $702.1M | $6.4B | +3.4% | 2 | +6.0% |
| HS 310420 - Fertilizers, mineral or chemical: potassic, potassium chloride | $10.1B | $717.7K | $6.4B | +805.1% | 3 | +0.0% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $4.7B | $18.5M | $6.1B | -11.2% | 3 | +0.3% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $12.0B | $1.5B | $6.0B | +41.5% | 3 | +7.0% |
| HS 293319 - Heterocyclic compounds: with nitrogen hetero-atom(s) only, containing an unfused pyrazole ring (whether or not hydrogenated) in the structure, other than henazone (antipyrin) and its derivatives | $2.6B | $5.0 | $5.1B | -91.5% | 1 | +0.1% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $871.2M | $5.0B | +12.6% | 3 | +6.1% |
| HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $4.2B | $13.8M | $4.8B | +7.6% | 1 | +0.3% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $251.3K | $4.1B | +4.2% | 2 | +0.0% |
| HS 290243 - Cyclic hydrocarbons: p-xylene | $8.5B | $1.4B | $3.9B | +13.5% | 1 | +16.6% |
| HS 290110 - Acyclic hydrocarbons: saturated | $2.0B | $8.2M | $3.8B | +12.6% | 1 | +0.4% |
| HS 283691 - Carbonates: lithium carbonate | $2.5B | $127.8K | $3.8B | +10.1% | 1 | +0.0% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $4.5B | $8.9M | $3.8B | +16.5% | 2 | +0.2% |
| HS 281820 - Aluminium oxide: other than artificial corundum | $3.5B | $263.4K | $3.4B | +35.6% | 2 | +0.0% |
| HS 290220 - Cyclic hydrocarbons: benzene | $4.1B | $180.6M | $3.2B | +11.9% | 1 | +4.4% |
| HS 282520 - Lithium oxide and hydroxide | $1.6B | $13.6K | $2.7B | -3.7% | 1 | +0.0% |
| HS 285390 - Phosphides, chemically defined or not, not ferrophosphorus: other inorganic compounds n.e.c. (including distilled, conductivity water and water of like purity): liquid air, rare gases removed or not: compressed air: amalgams, not precious metal amalgams | $1.3B | $15.5M | $2.3B | +23.6% | 1 | +1.2% |
| HS 282590 - Inorganic bases, metal oxides, hydroxides and peroxides: n.e.s. in heading no. 2825 | $1.5B | $25.4M | $2.3B | +6.8% | 1 | +1.7% |
| HS 290531 - Alcohols: acyclic, diols: ethylene glycol (ethanediol) | $3.2B | $6.3M | $2.2B | -5.0% | 1 | +0.2% |
| HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $1.5B | $1.7K | $2.1B | -10.3% | 1 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $18.7M | $2.0B | +5.0% | 1 | +0.5% |
| HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $9.7M | $1.9B | +0.5% | 1 | +0.4% |
| HS 284590 - Isotopes (excluding those of heading no. 2844): compounds, inorganic or organic, of such isotopes, whether or not chemically defined | $1.1B | $1.8K | $1.9B | -6.7% | 1 | +0.0% |
| HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $2.2M | $1.9B | +6.0% | 1 | +0.2% |
| HS 290121 - Acyclic hydrocarbons: unsaturated, ethylene | $1.8B | $301.6M | $1.8B | +18.5% | 1 | +16.5% |
| HS 310540 - Fertilizers, mineral or chemical: ammonium dihydrogenorthophosphate (monoammonium phosphate) and mixtures thereof with diammonium hydrogenorthophosphate (diammonium phosphate) | $2.7B | $331.2 | $1.8B | +22.3% | 1 | +0.0% |
| HS 380893 - Herbicides, anti-sprouting products and plant-growth regulators: not containing substances of 3808.50: put up in forms or packings for retail sale or as preparations or articles | $2.0B | $506.6K | $1.7B | -9.1% | 1 | +0.0% |
| HS 284420 - Uranium: enriched in U235, plutonium, their compounds, alloys dispersions (including cermets), ceramic products and mixtures containing uranium enriched in U235, plutonium or compounds of these products | $4.9B | $16.4M | $1.7B | -8.2% | 1 | +0.3% |
| HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $840.8M | $76.2K | $1.6B | +39.7% | 1 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $5.1B | $121.1M | $1.6B | +8.1% | 1 | +2.4% |
| HS 284690 - Compounds, inorganic or organic (excluding cerium), of rare-earth metals, of yttrium, scandium or of mixtures of these metals | $1.4B | $17.3M | $1.5B | +10.1% | 1 | +1.2% |
| HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $43.8K | $1.4B | -8.3% | 1 | +0.0% |
| HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.6B | $133.5K | $1.4B | +19.4% | 1 | +0.0% |
| HS 290122 - Acyclic hydrocarbons: unsaturated, propene (propylene) | $1.6B | $291.8M | $1.4B | +17.2% | 1 | +18.1% |
| HS 291736 - Acids: aromatic polycarboxylic acids: terephthalic acid and its salts | $1.6B | $60.7 | $1.4B | -12.7% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $655.9K | $1.4B | +10.8% | 1 | +0.1% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $140.4B calculated opportunity across 20 products.
- China (CHN): $49.1B calculated opportunity across 18 products.
- Slovenia (SVN): $42.8B calculated opportunity across 6 products.
- Germany (DEU): $40.1B calculated opportunity across 13 products.
- Switzerland, Liechtenstein (CHE): $33.1B calculated opportunity across 3 products.
- Belgium (BEL): $26.0B calculated opportunity across 4 products.
- Italy (ITA): $23.8B calculated opportunity across 4 products.
- Netherlands (NLD): $19.6B calculated opportunity across 5 products.
- Canada (CAN): $11.7B calculated opportunity across 6 products.
- United Kingdom (GBR): $10.8B calculated opportunity across 5 products.
- Mexico (MEX): $9.3B calculated opportunity across 4 products.
- France (FRA): $9.0B calculated opportunity across 4 products.

## Growth stars

- HS 310420: +805.1% average CAGR, $6.4B calculated opportunity.
- HS 284190: +84.6% average CAGR, $9.4B calculated opportunity.
- HS 382600: +50.0% average CAGR, $8.9B calculated opportunity.
- HS 382499: +41.5% average CAGR, $6.0B calculated opportunity.
- HS 381800: +39.7% average CAGR, $1.6B calculated opportunity.
- HS 281820: +35.6% average CAGR, $3.4B calculated opportunity.
- HS 285390: +23.6% average CAGR, $2.3B calculated opportunity.
- HS 310540: +22.3% average CAGR, $1.8B calculated opportunity.
- HS 284410: +19.4% average CAGR, $1.4B calculated opportunity.
- HS 290121: +18.5% average CAGR, $1.8B calculated opportunity.

## Diversification opportunities

- HS 300490: 17 buyer markets, $102.5B calculated opportunity.
- HS 300215: 13 buyer markets, $53.1B calculated opportunity.
- HS 300439: 7 buyer markets, $14.4B calculated opportunity.
- HS 300220: 5 buyer markets, $21.6B calculated opportunity.
- HS 300212: 5 buyer markets, $14.9B calculated opportunity.
- HS 293719: 4 buyer markets, $48.0B calculated opportunity.
- HS 300214: 4 buyer markets, $33.1B calculated opportunity.
- HS 284190: 4 buyer markets, $9.4B calculated opportunity.
- HS 382600: 4 buyer markets, $8.9B calculated opportunity.
- HS 293359: 3 buyer markets, $23.0B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.